Mesoblast Limited
ASX:MSB.AX
1.79 (AUD) • At close November 14, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Mesoblast Limited |
Symbool | MSB.AX |
Munteenheid | AUD |
Prijs | 1.795 |
Beurswaarde | 2,048,520,589 |
Dividendpercentage | 0% |
52-weken bereik | 0.255 - 1.82 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) |
Website | https://www.mesoblast.com |
An error occurred while fetching data.
Over Mesoblast Limited
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)